Literature DB >> 2995906

S-100 protein as a marker for melanocytic and other tumours.

A J Cochran, D R Wen.   

Abstract

The majority of melanocytic tumours are easily diagnosed but they become a problem when they are amelanotic and the tumour cells resemble those of other tumours. This applies particularly to secondary melanoma. Detection of S100 protein is a useful identifying marker. S100 protein, so named for its solubility in saturated ammonium sulphate, is derived from brain tissue. It is a dimer and belongs to a calcium binding group of proteins. The protein was first thought to be in neural or neural crest derived tissues but has been found in chondrocytes, adipocytes, myoepithelial cells, dendritic cells of lymphoid tissue, Langerhans cells and T lymphocytes. The protein is present in a high proportion of malignant melanomas and nevocytic nevi of skin, but is less positive in eye melanomas. It is present in gliomas, Schwannomas and neurofibromas but not in neurone derived tumours such as neuroblastomas. Chondromas, chondrosarcomas, liposarcomas, some osteogenic sarcomas and some histiocytic tumours are positive. The tumours that do not contain S100 protein are listed. Pending development of melanoma-directed monoclonal antibodies, the use of anti-serum to S100 protein plus anti-keratin and anti-leukocyte reagents is useful in the identification of tumours of doubtful histogenesis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995906     DOI: 10.3109/00313028509063777

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  14 in total

1.  Diagnostic immunopathology.

Authors:  P A Cancilla; A J Cochran; F Naeim; J W Said
Journal:  West J Med       Date:  1986-07

2.  Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.

Authors:  R King; K N Weilbaecher; G McGill; E Cooley; M Mihm; D E Fisher
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

3.  Serum S100beta protein as a marker of disease activity in patients with malignant melanoma.

Authors:  M Q Mohammed; H D Abraha; R A Sherwood; K MacRae; S Retsas
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

4.  Monoclonal antibodies in detection of choroidal melanoma.

Authors:  P J Ringens; R van Haperen; C Vennegoor; P T de Jong; S G van Duinen; D J Ruiter; A W van der Kamp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

5.  S-100 protein stimulates cellular proliferation.

Authors:  J R Klein; D S Hoon; J Nangauyan; E Okun; A J Cochran
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Targeting the cyclin-dependent kinase 5 in metastatic melanoma.

Authors:  Samanta Sharma; Tian Zhang; Wojciech Michowski; Vito W Rebecca; Min Xiao; Roberta Ferretti; Jan M Suski; Roderick T Bronson; Joao A Paulo; Dennie Frederick; Anne Fassl; Genevieve M Boland; Yan Geng; Jacqueline A Lees; Rene H Medema; Meenhard Herlyn; Steven P Gygi; Piotr Sicinski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-19       Impact factor: 11.205

7.  The radiosensitivity of uveal melanoma cells and the cell survival curve.

Authors:  D Soulières; A Rousseau; M Tardif; M Larochelle; M Tremblay; L Vaillancourt; G Pelletier
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-02       Impact factor: 3.117

8.  Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.

Authors:  Hollis Viray; William R Bradley; Kurt A Schalper; David L Rimm; Bonnie E Gould Rothberg
Journal:  Arch Pathol Lab Med       Date:  2013-08       Impact factor: 5.534

9.  Detection and quantification of S-100 protein in ocular tissues and fluids from patients with intraocular melanoma.

Authors:  A J Cochran; G N Holland; R E Saxton; B E Damato; W R Foulds; H R Herschman; R Y Foos; B R Straatsma; W R Lee
Journal:  Br J Ophthalmol       Date:  1988-11       Impact factor: 4.638

Review 10.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.